Switch Accessibility Mode

eLearning Liver MRI

Presenters: Elmar M. Merkle, Matthias R. Benz, Christoph J. Zech, Daniel T. Boll from the University of Basel, Switzerland

Applications of liver MRI and the Role of Primovist® Enhancement

Primovist® – or gadoxetic acid – is a gadolinium-based contrast agent indicated for liver MRI. Primovist®-enhanced MRI has gained an important place in clinical practice and changed the way that liver imaging is performed, as a consequence of its unique imaging characteristics and clinical applications.

This webinar, presented by experts from the University of Basel, consists of an introduction and four parts that describe the applications of liver MRI and the role of Primovist® enhancement:

PART 1

Value of Different Modalities

Presenter: Matthias R. Benz, Clinic of Radiology and Nuclear Medicine, Basel.

Duration: 25:37 min

 

PART 2

Gadoxetic Acid – Product Characteristics and Mode of Action.

Presenter: Christoph J. Zech, University of Basel.

Duration: 31:12 min

 

PART 3

Use of Hepatobiliary MRI in the Setting of Patients WITH Liver Cirrhosis

Presenter: Daniel T. Boll, University of Basel.

Duration: 19:13 min

 

PART 4

Use of Hepatobiliary MRI in the Setting of Patients WITHOUT Liver Cirrhosis

Presenter: Christoph J. Zech, University of Basel.

Duration: 39:12 min

 

Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol. 2006;6(3):244-51.

Bohte AE et al. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2011;21(1):87-97.

Boll DT, Merkle EM. Diffuse liver disease: strategies for hepatic CT and MR imaging. RadioGraphics. 2009;29(6):1591-614

Choi JS et al. Diffusion-weighted MR imaging of liver on 3.0-Tesla system: effect of intravenous administration of gadoxetic acid disodium. Eur Radiol. 2010;20(5):1052-60.

Dalrymple NC. Problem Solving in Abdominal Imaging. Elsevier, 1st edition 2009. ISBN: 9780323043533.

Ernst O et al. Hepatic iron overload: diagnosis and quantification with MR imaging. AJR Am J Roentgenol. 1997;168(5):1205-8.

Gandon Y et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363(9406):357-62.

Gonzalez-Guindalini FD et al. Assessment of liver tumor response to therapy: role of quantitative imaging. Radiographics. 2013; 33(6):1781-800.

St Pierre TG et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855-61.

Torres DM et al. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10(8):837-58.

Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901-10.

Website:

Bashir MR, Merkle EM. Improved liver lesion conspicuity by increasing the flip angle during hepatocyte phase MR imaging. Eur Radiol. 2011;21(2):291-4.

Choi JS et al. Diffusion-weighted MR imaging of liver on 3.0-Tesla system: effect of intravenous administration of gadoxetic acid disodium. Eur Radiol. 2010;20(5):1052-60.

Kim YK et al. Detection and characterization of focal hepatic tumors: a comparison of T2-weighted MR images before and after the administration of gadoxetic acid. JMRI. 2009;30(2):437-43.

Lauenstein T et al. Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study. Invest Radiol. 2015;50(6):416-22.

Rohrer M et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40(11):715-24.

Saito K et al. Effect of Gd-EOB-DTPA on T2-weighted and diffusion-weighted images for the diagnosis of hepatocellular carcinoma. JMRI. 2010;32(1):229–34.

Schmid-Tannwald C, Zech CJ, et al. Presentation at ESMRMB, 2009.

Van der Borght S et al. Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver. J Pathol. 2005;207(4):471-82.

Zech CJ et al. Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol. 2009;44(6):305-10.

Website: